Clinical Trials Logo

Clinical Trial Summary

Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with relapsed or refractory (R/R) FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 3 groups, called treatment arms. Each group receives a different treatment. Around 642 adult participants with R/R FL will be enrolled in approximately 300 sites across the world. Participants will receive R2 (intravenous infusion of rituximab up to 5 cycles and oral capsules of lenalidomide for up to 12 cycles) alone or in combination with subcutaneous injections of epcoritamab for up to 12 cycles (each cycle is 28 days). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05409066
Study type Interventional
Source AbbVie
Phone 844-663-3742
Email [email protected]
Status Not yet recruiting
Phase Phase 3
Start date September 7, 2022
Completion date December 27, 2029

See also
  Status Clinical Trial Phase
Completed NCT03571828 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma Phase 1
Recruiting NCT02914938 - A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma Phase 1
Recruiting NCT04049513 - ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) Phase 1
Recruiting NCT03869619 - REal World Data in LYmphoma and Survival in Adults
Recruiting NCT04830137 - A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies Phase 1
Recruiting NCT03547115 - A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies or AML Phase 1
Not yet recruiting NCT04767308 - Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies Early Phase 1
Recruiting NCT03768505 - Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) Phase 2
Recruiting NCT03265158 - Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0 N/A
Enrolling by invitation NCT04488354 - Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T Phase 1
Active, not recruiting NCT02362035 - ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Phase 1/Phase 2
Active, not recruiting NCT02875548 - Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study Phase 1/Phase 2
Recruiting NCT04450069 - CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies Phase 1
Recruiting NCT04745832 - Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) Phase 3
Active, not recruiting NCT04537715 - A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat Phase 1
Recruiting NCT03460977 - PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Phase 1
Recruiting NCT05131022 - A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies Phase 1